ANI PHARMACEUTICALS INC — Director's Dealing 2013

Jun 21, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOSANTE PHARMACEUTICALS INC (bpax)
CIK: 0001023024
Period of Report: 2013-06-19

Reporting Person: MARSHBANKS TRACY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-06-19	Common Stock	A	3314964	—	Acquired	3314964	Indirect
2013-06-19	Common Stock	A	138091	—	Acquired	138091	Indirect
2013-06-19	Common Stock	A	1345812	—	Acquired	1345812	Indirect
2013-06-19	Common Stock	A	51778	—	Acquired	51778	Indirect

Footnotes

F1: On June 19, 2013, the issuer's wholly-owned subsidiary merged with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a privately-held Delaware corporation (ANI). Holders of ANI's series D preferred stock received shares of the issuer's common stock as merger consideration. FA Private Equity Fund IV, L.P., a former holder of ANI series D preferred stock, acquired shares of issuer common stock in exchange for its shares of ANI series D preferred stock.

F2: 1: Held by: FA Private Equity Fund IV, L.P., of which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).

F3: On June 19, 2013, the issuer's wholly-owned subsidiary merged with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a privately-held Delaware corporation (ANI). Holders of ANI's series D preferred stock received shares of the issuer's common stock as merger consideration. FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, a former holder of ANI series D preferred stock, acquired shares of issuer common stock in exchange for its shares of ANI series D preferred stock.

F4: Held by: FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, of which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).

F5: On June 19, 2013, the issuer's wholly-owned subsidiary merged with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a privately-held Delaware corporation (ANI). Holders of ANI's series D preferred stock received shares of the issuer's common stock as merger consideration. The Productivity Fund IV Liquidating Trust, a former holder of ANI series D preferred stock, acquired shares of issuer common stock in exchange for its shares of ANI series D preferred stock.

F6: Held by: The Productivity Fund IV Liquidating Trust, of which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).

F7: On June 19, 2013, the issuer's wholly-owned subsidiary merged with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a privately-held Delaware corporation (ANI). Holders of ANI's series D preferred stock received shares of the issuer's common stock as merger consideration. The Productivity Fund IV Advisors Fund Liquidating Trust, a former holder of ANI series D preferred stock, acquired shares of issuer common stock in exchange for its shares of ANI series D preferred stock.

F8: Held by: The Productivity Fund IV Advisors Fund Liquidating Trust, of which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).